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Epstein-Barr virus (EBV)-encoded nuclear antigen 1
(EBNA1) includes a unique glycine-alanine repeat do-
main that inhibits the endogenous presentation of cyto-
toxic T lymphocyte (CTL) epitopes through the class I
pathway by blocking proteasome-dependent degrada-
tion of this antigen. This immune evasion mechanism
has been implicated in the pathogenesis of EBV-associ-
ated diseases. Here, we show that cotranslational ubiq-
uitination combined with N-end rule targeting enhances
the intracellular degradation of EBNA1, thus resulting
in a dramatic reduction in the half-life of the antigen.
Using DNA expression vectors encoding different forms
of ubiquitinated EBNA1 for in vivo studies revealed that
this rapid degradation, remarkably, leads to induction
of a very strong CTL response to an EBNA1-specific CTL
epitope. Furthermore, this targeting also restored the
endogenous processing of HLA class I-restricted CTL
epitopes within EBNA1 for immune recognition by hu-
man EBV-specific CTLs. These observations provide, for
the first time, evidence that the glycine-alanine repeat-
mediated proteasomal block on EBNA1 can be reversed
by specifically targeting this antigen for rapid degrada-
tion resulting in enhanced CD8 T cell-mediated recog-
nition in vitro and in vivo.
Epstein-Barr virus (EBV)1 establishes a highly immunogenic
growth-transforming infection of B lymphocytes associated
with the co-ordinate expression of virus-encoded nuclear anti-
gens (referred to as EBNA1–EBNA6). This latent growth-
transforming infection elicits a strong CD8 cytotoxic T lym-
phocyte (CTL) response directed against all the nuclear
antigens except EBNA1 (1–3). EBNA1 is the only viral protein
regularly detected in all EBV-associated malignancies (re-
viewed in Ref. 4). It is now well established that EBNA1 is
poorly recognized by the CD8 CTL-mediated surveillance
that prevents the uncontrolled proliferation of EBV-infected B
cells in vivo (1–3). Furthermore, mammary carcinoma cells
transfected with EBNA1 are poorly immunogenic in mice,
whereas strong immunogenicity was induced by expression of
other EBV proteins that are highly immunogenic in humans,
suggesting that CTL evasion occurs across species (5).
Studies by Levitskaya et al. (6) showed that an internal
glycine-alanine repeat (GAr) domain of EBNA1 acts as a cis-
inhibitor of MHC class I-restricted presentation. They proposed
that the sequence within the EBNA1 GAr domain may influ-
ence the folding pattern of this antigen and affect its capacity to
associate with various components of the ubiquitin/proteasome
pathway, including ubiquitin conjugation enzymes and/or reg-
ulatory subunits of the proteasome. More recent studies by
Sharipo et al. (7) have shown that although the GAr sequence
allows ubiquitination when inserted into the IB protein se-
quence, the polyubiquitinated protein is unable to form stable
complexes with the proteasome. Based on these observations, it
was argued that the GAr domain forms -sheets that are re-
sistant to unfolding and that block entry into the proteasomal
complex.
Prompted by these observations, we constructed a series of
EBNA1 expression vectors to determine whether any strate-
gies could be devised to override this GAr-mediated inhibition
of MHC class I-restricted presentation of EBNA1. Based on our
understanding of proteasomal targeting of cellular and viral
proteins (8, 9), these expression vectors were specifically de-
signed to target EBNA1 through the ubiquitin/proteasome
pathway to enhance its intracellular degradation. Here, we
report that covalent linking of EBNA1 with ubiquitin and
targeting to the N-end rule pathway dramatically enhances its
intracellular degradation and restores CD8 T cell recognition.
EXPERIMENTAL PROCEDURES
Construction of Ubiquitin-EBNA1 Chimeras—Full-length EBNA1
was cloned into the expression vector pcDNA3.1 (Invitrogen, San Diego,
CA) to generate EBNA1 (Fig. 1A), which encodes nonubiquitinated
EBNA1 protein. To generate noncleavable ubiquitin conjugates of
EBNA1 in pcDNA3.1, a vector was constructed expressing the EBNA1
coding sequence, EBNA1, fused in-frame to the C terminus of the
human ubiquitin-coding sequence. The C-terminal glycine residue
(Gly76) of human ubiquitin was mutated to an alanine residue (Ala76),
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which diminishes cleavage of the fusion protein (8), generating Ub-Ala/
Met-EBNA1 (Fig. 1B). In addition, we constructed an expression vector,
Ub-Ala/Arg-EBNA1 (Fig. 1C) in which the ubiquitin-Ala76 conjugate of
EBNA1 was expressed in such a way that the N-terminal residue of
EBNA1 was modified from Met1 to Arg1. The latter substitution applies
the principles of N-end rule targeting and has been shown to decrease
the in vivo half-life of a protein from greater than 10 h to 3 min (10). For
comparison, Arg1-EBNA1 was also fused in-frame to the C terminus of
unmodified ubiquitin-Gly76 to generate the expression vector Ub-Gly/
Arg-EBNA1 (Fig. 1D). Similarly, Met1-EBNA1 was also fused in-frame
to the C terminus of unmodified ubiquitin-Gly76 to generate the expres-
sion vector Ub-Gly/Met-EBNA1 (Fig. 1F). In addition, we constructed
an EBNA1 construct in which the GAr domain was deleted, EBNA1-
GAr-del (Fig. 1J). The above constructs included insertion of a well
defined HLA-B8-restricted, EBNA-3 CTL epitope, FLRGRAYGL (re-
ferred to as FLR) (21) into the SacII site at nucleotide position 1853 of
EBNA1, to allow evaluation of endogenous processing of EBNA1 by
using specific CTL clones. To assess expression of EBNA1, EBNA1-
GAr-del, and Ub-EBNA1, each of the inserts from the above pcDNA3.1
constructs was subcloned in-frame with a sequence coding for green
fluorescent protein (pEGFP-N1, CLONTECH, Palo Alto, CA); EBNA1-
GFP (Fig. 1E), Ub-Gly/Met-EBNA1-GFP (Fig. 1F), Ub-Ala/Met-EBNA1-
GFP (Fig. 1G), Ub-Ala/Arg-EBNA1-GFP (Fig. 1H), Ub-Gly/Arg-EBNA1-
GFP (Fig. 1I), and EBNA1-GAr-del-GFP (Fig. 1J).
Transfection of EBNA1 and Ub-EBNA1 Expression Constructs—Re-
combinant EBNA1 and Ub-EBNA1 constructs were transiently trans-
fected into either an EBV-negative Burkitt’s lymphoma B-cell line
(DG75), an EBV-transformed lymphoblastoid cell line (LCL-KK/B95.8),
or an EBV-negative keratinocyte cell line (SVMR6). Exponentially
growing DG75 or KK/B95.8-LCL cells (5  106) were transfected in
growth medium with 10 g of DNA using the Bio-Rad Gene Pulser (960
F, 250 V, 0.4 cm gap electrode, 300 l assay volume; 25EC). SVMR6
keratinocytes were also transfected with the pcDNA3.1 expression con-
structs (Fig. 1, A–D) using LipofectAMINE (Invitrogen Life Technolo-
gies, Inc.) according to the manufacturer’s instructions. Two protea-
some inhibitors, Cbz-leu-leu-leucinal (Cbz-L3) and N-acetyl-leucyl-
leucyl-norleucinal, were added to the cells at a final concentration of 10
and 2 g/ml, respectively, 24 h after the commencement of transfection.
The efficiency of transfection and the effect of proteasome inhibitors on
the transfected cells were assessed by FACScan (Becton Dickinson, San
Jose, CA) set to measure GFP fluorescence and analyzed with the
Cellquest software (Becton Dickinson).
Degradation of EBNA1 and Ub-EBNA1 Proteins in DG75 Cells—
DG75 cells were transiently transfected with EBNA1-GFP, Ub-Gly/
Met-EBNA1-GFP, Ub-Ala/Met-EBNA1-GFP, Ub-Ala/Arg-EBNA1-GFP,
Ub-Gly/Arg-EBNA1-GFP, EBNA1-GFP-GAr-del, and pEGFP-N1 ex-
pression vectors as described above. At 30 h posttransfection, cyclohex-
imide (25 g/ml) was added to 8  106 cells. Equal aliquots of cells were
removed at time points 0 min, 30 min, 1 h, and 2 h; lysed in SDS-
polyacrylamide gel electrophoresis sample dye; and resolved under
reducing conditions on a 7.5% SDS-polyacrylamide gel.
Detection of EBNA1 and Ub-EBNA1 by Immunoblotting—Cell ly-
sates were prepared by homogenizing 1  107 cells suspended in 0.2 ml
of 1% SDS/phosphate-buffered saline with a 27 gauge needle. The
samples were run on SDS-polyacrylamide gel electrophoresis and elec-
troblotted onto a nitrocellulose membrane, (Hybond C, Amersham
Pharmacia Biotech) and incubated with anti-GFP serum (1:2000) or
anti-actin antibody (1:1000).
DNA Immunization—DNA was purified using the Qiagen endotoxin-
free maxi-prep kit. 6–8-week-old female BALB/c (H-2d) mice were
immunized intramuscularly three times, at 14-day intervals, with 50
g of plasmid DNA. This was dissolved in endotoxin free phosphate-
buffered saline at a concentration of 1 g/ml, and 50 l was injected into
the rear quadriceps muscle using a 28 gauge needle. For the constructs
EBNA1, Ub-Ala/Met-EBNA1, and Ub-Ala/Arg-EBNA1, five mice were
used in each treatment group. For the pcDNA3.1 vector control and
Ub-Gly/Arg-EBNA1, three mice per group were used. Five weeks after
the final DNA immunization, mice were killed by cervical dislocation,
and spleens were removed for in vitro restimulation of CTLs.
Assay for EBNA1-specific CTL Response—Splenocytes (16  106)
from each mouse were seeded into four wells of a 24-well plate and
mixed with peptide-coated (10 g/ml) -irradiated (2000 rads) LPS blasts
(derived from naive Balb/c splenocytes) at a responder to stimulator
ratio of 3:1. The H-2Kd-restricted, EBNA1 peptide epitope is
VYGGSKTSL (12). After 5 days, the responder cells were harvested,
and viable cells were counted. 51Cr-labeled P815 target cells (a H-2d-
positive mastocytoma cell line) were incubated in the presence or ab-
sence of the EBNA1 peptide epitope and used as targets in a standard
cytotoxicity assay (11).
RESULTS
Covalent Linkage of Ubiquitin with EBNA1 Dramatically
Reduces the Intracellular Stability of EBNA1—There is now
convincing evidence that proteasomal degradation of intracel-
lular proteins is critically dependent on the covalent linkage of
ubiquitin via its C-terminal glycine residue (Gly76) to -amino
groups on lysine residues on the protein substrate, followed by
rapid polyubiquitination through the attachment of additional
ubiquitin molecules (13–15). Because previous studies have
suggested that inefficient targeting of EBNA1 through the
ubiquitin/proteasome pathway may be responsible for poor en-
dogenous processing, we reasoned that covalent linkage of
EBNA1 to ubiquitin may allow efficient targeting of this pro-
tein to the proteasomal complex. To further enhance the pro-
teasomal targeting of our ubiquitinated EBNA1 constructs, we
have mutated the Gly76 residue of ubiquitin to Ala76, which is
known to diminish the cleavage of the fusion protein by greater
than 90% (16) while still permitting the fused ubiquitin to act
as a substrate for polyubiquitination. In addition to the above
modification, we have constructed expression vectors in which
ubiquitin conjugates of EBNA1 are expressed in such a way as
to generate proteins with N-terminal amino acids other than
methionine. Previous studies showed that changing the
N-terminal amino acid of a protein (N-end rule targeting)
(17) can result in a markedly altered stability of that protein
(10, 18–20).
Fig. 1 shows a schematic representation of the EBNA1 con-
structs used in this study. To determine the intracellular ki-
netics of ubiquitinated EBNA1, an EBV-negative B cell line
(DG75) was transiently transfected with expression vectors
pEGFP-N1, EBNA1-GFP, Ub-Gly/Met-EBNA1-GFP, Ub-Ala/
Arg-EBNA1-GFP, Ub-Gly/Arg-EBNA1-GFP, Ub-Ala/Met-
EBNA1-GFP, or EBNA-GAr-del-GFP, and protein expression
was analyzed by SDS-polyacrylamide gel electrophoresis fol-
lowing incubation with cycloheximide. The intensity of
EBNA1-GFP band was measured by densitometric analysis.
Representative data from this analysis are shown in Fig. 2.
Full-length EBNA1-GFP and GFP were highly stable in these
cells, and even after a 120-min chase, 90% of the protein was
detectable (Fig. 2, A and G). In contrast, cells transfected with
the expression vectors Ub-Ala/Arg-EBNA1-GFP, Ub-Gly/Arg-
EBNA1-GFP, Ub-Ala/Met-EBNA1-GFP, or EBNA-GAr-del-
GFP showed a dramatic reduction in the stability of EBNA1,
with almost 50% of the protein being degraded within the first
60 min (Fig. 2, C–F, and Fig. 3). By 120 min, 60–80% of the
protein was degraded. EBNA1-GFP protein in cells transfected
with the Ub-Gly/Met-EBNA1-GFP construct was relatively sta-
ble, with only 20% degradation within the first 60 min (Figs. 2B
and 3). Densitometric analysis indicated that the half-life for
the native form of the EBNA1 was 120 min, whereas the
half-life for the ubiquitinated forms with strong degradation
signals and also the GAr-deleted form of EBNA1 was between
60 and 120 min (Fig. 3). To demonstrate that the expression of
the Ub-EBNA1-GFP protein does not effect cell viability, the
immunoblots were also probed with a specific antibody to dem-
onstrate the stability of actin over the time course of the ex-
periment. Representative data from the EBNA1-GAr-del cyclo-
heximide-treated transfectants are shown in Fig. 2H. A similar
pattern of stable actin expression was also observed for the
other transfectants (data not shown). Notably, the cells trans-
fected with Ub-Ala/Met-EBNA1-GFP construct showed two dis-
tinct species, whereas other ubiquitinated forms of EBNA1
showed a single species (Fig. 2). Both of these species showed
an identical pattern of degradation. It is possible that the low
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molecular weight polypeptide may be derived from a distinct
cleavage event.
To confirm these results, each of the transfectants were
incubated with the proteasome inhibitor Cbz-L3. As shown in
Fig. 4, full-length EBNA1 fusion proteins were readily detected
in DG75 cells transfected with the EBNA1-GFP and Ub-Gly/
Met-EBNA1-GFP expression constructs, and their expression
remained unaffected following treatment of the transfected
cells with the proteasome inhibitor Cbz-L3. In contrast, cells
transfected with the Ub-Ala/Met-EBNA1-GFP, Ub-Ala/Arg-
EBNA1-GFP, or Ub-Gly/Arg-EBNA1-GFP constructs displayed
low levels of full-length EBNA1-GFP fusion proteins, indicat-
ing that specific targeting of EBNA1 through the proteasomal
pathway dramatically reduced the stability of this protein.
Incubation of these transfected cells with Cbz-L3 led to the
detection of significantly enhanced levels of EBNA1-GFP (Fig.
4). Thus, Cbz-L3 prevents intracellular degradation of the
ubiquitinated EBNA1-GFP fusion proteins targeted through
the proteasomal pathway.
Consistent with the immunoblot assays, GFP fluorescence
analysis by FACScan of DG75 cells transfected with the ex-
pression vectors encoding EBNA1-GFP, Ub-Ala/Met-EBNA1-
GFP, Ub-Ala/Arg-EBNA1-GFP, or Ub-Gly/Arg-EBNA1 also
showed a similar pattern of expression in the presence or
absence of the Cbz-L3 inhibitor. Representative data from this
analysis are shown in Fig. 5. The number of GFP-positive cells
following transfection with the EBNA1-GFP construct re-
mained constant over the 48-h period and increased slightly
following treatment with proteasome inhibitor Cbz-L3. In con-
trast, a reduction in the number of GFP-positive cells was seen
over the 48 h period when DG75 cells were transfected with
Ub-Ala/Met-EBNA1, Ub-Ala/Arg-EBNA1, or Ub-Gly/Arg-
EBNA1, whereas the number of GFP-positive cells increased
significantly in the presence of the proteasome inhibitor (Fig.
5). It is important to point out that the number of GFP-positive
cells following transfection with ubiquitin-conjugated EBNA1
constructs was consistently lower compared with cells trans-
fected with the EBNA1-GFP construct. This was presumably
due to the enhanced degradation of EBNA1 through the pro-
teasome pathway. To ensure that these results were not influ-
enced by the transfection efficiency of the individual con-
structs, we conducted a longitudinal analysis (at the indicated
time points) of GFP expression for each construct in the pres-
ence or absence of Cbz-L3. Data from this analysis are pre-
sented as the relative percentage of GFP-positive cells (Fig. 6).
It is clear from this analysis that the number of GFP-positive
cells following transfection with the EBNA1-GFP construct
remained almost constant from 24 h posttransfection (PT) to
48 h PT. On the other hand, a gradual reduction in relative
GFP-positive cells was observed for Ub-Ala/Met-EBNA1, Ub-
Ala/Arg-EBNA1, and Ub-Gly/Arg-EBNA1 transfectants. This
reduction was more pronounced in DG75 cells transfected with
the Ub-Gly/Arg-EBNA1 construct. A reversal in this reduction
of GFP-positive cells was seen following treatment of these
transfectants with Cbz-L3 (Fig. 6). Although some increase in
relative GFP-positive cells was seen for EBNA1-GFP transfec-
tants in the presence of Cbz-L3, this increment was clearly
more enhanced in ubiquitin-conjugated EBNA1 constructs. A
similar effect on GFP expression was also observed in the
presence of another proteasome inhibitor N-acetyl-leucyl-
leucyl-norleucinal (data not shown). These data clearly demon-
strate that covalent linkage to ubiquitin and N-end rule tar-
geting of EBNA1 overrides the GAr-mediated inhibitory effect
on the proteasome-mediated intracellular degradation and
thus may enhance endogenous presentation of CTL epitopes
from EBNA1.
Covalent Ubiquitin Linkage and N-end Rule Targeting Dra-
matically Enhance the EBNA1-specific CTL Response in
Vivo—To test the hypothesis that the rapid degradation of
EBNA1 through the ubiquitin-proteasomal pathway may en-
hance de novo CTL responses in vivo, five different groups of
BALB/c mice were immunized with plasmid DNA vectors
encoding either EBNA1, Ub-Ala/Met-EBNA1, Ub-Ala/Arg-
EBNA1, Ub-Gly/Arg-EBNA1, or pcDNA3.1 vector alone. Fol-
lowing immunization, the CTL response against an H-2Kd-
restricted EBNA1 CTL epitope (VYGGSKTSL) (12) was
assessed. As shown in Fig. 7, mice immunized with the EBNA1
plasmid consistently showed low to undetectable levels of CTL
activity against the VYGGSKTSL epitope (Fig. 7A). Detection
of low levels of EBNA1-specific responses in mice immunized
with native forms of EBNA1 is consistent with the earlier
observation in humans, in which occasional EBNA1-specific
responses have also been detected in healthy virus carriers
(22). In contrast, a significantly enhanced EBNA1-specific CTL
response was observed following immunization with expression
vectors encoding ubiquitinated EBNA1 (Ub-Ala/Met-EBNA1,
Ub-Ala/Arg-EBNA1, and Ub-Gly/Arg-EBNA1) (Fig. 7, B–D, re-
spectively). No EBNA1-specific CTL response was detected in
FIG. 1. Schematic description of EBNA1 and Ub-EBNA1 ex-
pression constructs. Ten plasmids expressing EBNA1 were gener-
ated in either pcDNA3.1 (A–D) or in pEGFP-N1 (E–J) as described
under “Experimental Procedures.” A, full-length EBNA1; B, EBNA1 as
a covalent fusion with the ubiquitin gene (the native C-terminal amino
acid residue of the Ub moiety has been mutated from Gly76 to Ala76
(Ub-Ala/Met-EBNA1)); C, EBNA1 as a covalent fusion with Ub-Ala76 in
which the N-terminal residue for EBNA1 is substituted from methio-
nine to arginine (Ub-Ala/Arg-EBNA1); and D, EBNA1 as a noncovalent
fusion with unmodified Ub-Gly76 in which EBNA1 has the unstable
N-terminal arginine residue (Ub-Gly/Arg-EBNA1). In addition, the
above constructs were fused in-frame to GFP at the C-terminal end. E,
native full-length EBNA1 (EBNA1-GFP); F, Ub-Gly/Met-EBNA1-GFP;
G, Ub-Ala/Met-EBNA1-GFP; H, Ub-Ala/Arg-EBNA1-GFP; I, Ub-Gly/
Arg-EBNA1-GFP; J, GAr-deleted EBNA1 (EBNA1-GAr-del). The above
constructs include insertion of a HLA-B8-restricted EBNA3 CTL
epitope, FLRGRAYGL, within the EBNA1 C-terminal sequence, which
allows analysis of endogenous processing of EBNA1 using FLR-specific
CTL clones.
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mice immunized with the pcDNA3.1 vector alone (data not
shown). Epitope-specific lysis by CTLs recovered from the ubiq-
uitinated EBNA1 mice was, on average, 2–3-fold higher than
that of CTLs recovered from mice immunized with EBNA1.
These results support the conclusions drawn from the data
shown in Figs. 2 and 5, as well as demonstrating that ubiquiti-
nation of EBNA1 enhances the presentation of CTL epitopes
within EBNA1, which in turn results in the induction of strong
epitope-specific CTL responses in vivo.
Specific Targeting of EBNA1 through the Ub-Proteasome
Pathway Restores Endogenous Processing of HLA Class I-re-
stricted CTL Epitopes within EBNA1—Although data pre-
sented in Fig. 7 clearly showed that rapid degradation of
EBNA1 can enhance in vivo CTL responses in a murine model,
it was important to further confirm these observations by using
human class I-restricted EBV-specific CTLs. As shown in Fig.
1, each of the EBNA1 constructs included an HLA B8-re-
stricted CTL epitope, FLR, within the EBNA1 C-terminal se-
quence, which allowed the study of endogenous processing of
EBNA1 using FLR-specific human CTL clones. An EBV-nega-
tive, HLA B8-positive human keratinocyte line (SVMR6) was
transfected with expression vectors encoding EBNA1, Ub-Ala/
FIG. 2. Ubiquitination enhances in-
tracellular degradation of EBNA1.
DG75 cells were transfected with expression
constructs EBNA1-GFP (A), Ub-Gly/Met-
EBNA1-GFP (B), Ub-Ala/Arg-EBNA1-GFP
(C), Ub-Gly/Arg-EBNA1-GFP (D), EBNA1-
GAr-del-GFP (E), Ub-Ala/Met-EBNA1-GFP
(F), and the control plasmid pEGFP-N1 (G).
At 30 h posttransfection, the cells were de-
graded over a 2-h time course in the pres-
ence of cycloheximide as described under
“Experimental Procedures.” The stability of
actin was monitored over the time course for
each of the above expression constructs, and
a representative immunoblot is shown in H.
Molecular weight standards are indicated at
the side of each panel.
FIG. 3. Densitometric analysis of
EBNA1-GFP expression. Band intensi-
ties were quantified by analysis of the
imaging data and plotted as a relative
percentage of the signal at time 0 for
EBNA1-GFP, Ub-Gly/Met-EBNA1-GFP,
Ub-Ala/Met-EBNA1-GFP, Ub-Ala/Arg-
EBNA1-GFP, Ub-Gly/Arg-EBNA1-GFP,
and EBNA1-GAr-del-GFP.
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Met-EBNA1, and Ub-Ala/Arg-EBNA1 or transfected with the
vector control pcDNA3.1. These transfectants were maintained
in RPMI 1640/10% fetal calf serum medium supplemented with
G418. Following G418 selection for 2–4 weeks, EBNA1 expres-
sion in transfectants was confirmed and tested for endogenous
processing of CTL epitopes in a standard 51Cr-release cytotox-
icity assay using a panel of three FLR-specific CTL clones.
Representative data from several different experiments are
shown in Fig. 8A. Consistent with previous studies (22),
SVMR6 cells transfected with the expression vector encoding
EBNA1 were poorly recognized by FLR-specific CTL clones, as
were SVMR6 cells transfected with the pcDNA3.1 expression
vector. This lack of immune recognition of EBNA1 transfec-
tants by FLR-specific CTL clones was not due to inadequate
antigen expression, as immunoblot analysis clearly showed
strong protein expression in these transfectants (data not
shown). In contrast, significantly higher lysis of SVMR6 trans-
fectants expressing ubiquitinated forms of EBNA1 (Ub-Ala/
Met-EBNA1 or Ub-Ala/Arg-EBNA1) was observed following
exposure to FLR-specific CTL clones LC13, DD1, and GA18
(Fig. 8A). It is important to point out that this increased lysis is
in accordance with the decreased stability of ubiquitinated
forms of EBNA1 (as shown in Figs. 2, 5, and 6), which results
in lower levels of EBNA1 expression in SVMR6 cells trans-
fected with the Ub-Ala/Arg-EBNA1 construct. Similar results
were also obtained with a B cell line transfected with these
expression vectors (data not shown). The FLR-specificity of this
CTL lysis was confirmed by the lack of immune recognition by
another HLA B8-restricted CTL clone, LC7, which is specific
for the QAKWRLQTL epitope (3) from EBV (Fig. 8A). CTL lysis
of transfectants expressing ubiquitinated EBNA1 (Ub-Ala/Arg-
EBNA1) was blocked following addition of the proteasome in-
hibitor, Cbz-L3 (Fig. 8B). Similarly, inhibition of epitope spe-
cific lysis of transfectants expressing ubiquitinated EBNA1
(Ub-Ala/Arg-EBNA1) protein was demonstrated following in-
cubation with an anti-class I antibody (W6/32) (Fig. 8B).
To exclude the possibility that the observed FLR-specific
CTL recognition was due to exogenously transferred EBNA1
protein or peptides, coculture experiments were conducted.
SVMR6 transfectants were mixed with a 51Cr-labeled, EBV-
transformed lymphoblastoid cell line (HLA B8-positive LC/
B95.8, which expresses a mutated form of FLR epitope) to test
for transfer of EBNA1 protein or FLR epitope from the trans-
fected SVMR6. The FLR-specific CTL clone LC13 was then
added, and lysis of 51Cr-labeled LC/B95.8 cells was assessed.
No lysis of LC/B95.8 cells was observed under these conditions.
Under identical conditions 51Cr-labeled SVMR6 transfectants
or peptide sensitized LC/B95.8 cells were efficiently recognized
(data not shown). Collectively, these observations demonstrate
that the GAr-mediated inhibitory effect on intracellular deg-
radation of EBNA1 can be reversed by specifically targeting
this protein through the ubiquitin/proteasome degradation
pathway.
DISCUSSION
Adaptation of a successful latent infection by lymphocrypto-
viruses, such as EBV, within the cells of the immune system
has been achieved by evolving unique mechanisms to negate
the hostile effects of the host immune system (2, 3, 5). One
classic example is the ability of the EBNA1 protein to inhibit
endogenous presentation of CTL epitopes derived from this
protein (6, 7, 12, 22, 23). This inhibitory effect is mediated by a
repeat sequence of glycine and alanine residues included
within the EBNA1 sequence (6). Recent studies have suggested
that the GAr forms -sheets that are resistant to unfolding and
thus block the entry of EBNA1 protein into the proteasome
complex (7). Because EBNA1 plays a crucial role in the main-
tenance of the EBV episome in latently infected normal and
malignant cells, protection from CTL-mediated immune control
may allow the reservoir of latently infected cells to seed other
cellular compartments, where EBV can replicate and be trans-
mitted. More importantly, the evasion of CTL-mediated im-
mune control may also explain how EBV-positive BL cells,
which express only EBNA1, can survive in immunocompetent
hosts (reviewed in Refs. 2 and 4). Thus, any strategies that are
capable of overriding the GAr-mediated inhibitory effect on the
intracellular degradation of EBNA1 may have important im-
plications for developing therapeutic protocols for the treat-
ment of EBV-associated malignancies.
In the present study, we have targeted EBNA1 through the
ubiquitin-proteasome pathway to enhance its intracellular deg-
radation. This approach was primarily designed on the earlier
insights into proteasomal targeting of cellular and other viral
proteins (8). Considering the importance of stable ubiquitina-
tion on intracellular degradation of cellular proteins, we rea-
soned that covalent linkage of ubiquitin combined with N-end
rule targeting may allow efficient unfolding of EBNA1 and
subsequent degradation by the proteasomal complex. This
hypothesis was also supported by the previous studies of
Levitskaya et al. (23), who showed that the EBNA1 polypeptide
is poorly ubiquitinated in vitro. Indeed, we show here that this
approach is extremely effective in overriding the GAr-mediated
inhibitory effect on EBNA1 degradation in human cells. Due to
effective proteasomal degradation, covalently linked ubiquiti-
nated forms of EBNA1 are rapidly degraded in transfected
cells, but this low expression is completely reversed in the
presence of a ubiquitin-proteasome inhibitor Cbz-L3. Kinetic
analysis indicated that covalent linking of ubiquitin in combi-
nation with N-end rule targeting dramatically reduces the in-
tracellular half-life of EBNA1. These results provided a first
indication that EBNA1 may not be completely resistant to
proteasomal degradation as previously proposed. More impor-
tantly, the data also suggested that rapid turnover may lead to
the presentation of class I-restricted CTL epitopes within
EBNA1.
To explore this possibility, we first tested the efficacy of
ubiquitinated EBNA1 to induce epitope-specific CTL responses
in vivo in a murine model. Expression vectors for three differ-
ent forms of ubiquitinated EBNA1 and a native EBNA1 were
used to immunize different groups of mice. Distinct forms of
ubiquitinated EBNA1 allowed us to test whether the covalent
linkage and/or N-end rule targeting of EBNA1 was essential to
enhance the priming of the EBNA1-specific CTL response in
vivo. As expected, immunization with expression vectors encod-
ing native forms of EBNA1 failed to generate any significant
CTL response, whereas all three expression vectors encoding
different forms of ubiquitinated EBNA1 induced dramatically
FIG. 4. Effect of the proteasomal inhibitor Cbz-L3 on the sta-
bility of EBNA1. Duplicate aliquots of DG75 cells were transfected
with control plasmid pEGFP-N1 (lanes 1 and 2) or expression con-
structs EBNA1-GFP, Ub-Gly/Met-EBNA1-GFP, Ub-Ala/Met-EBNA1-
GFP, Ub-Ala/Arg-EBNA1-GFP, and Ub-Gly/Arg-EBNA1-GFP; 36 h
later, the proteasome inhibitor Cbz-L3 was added at a final concentra-
tion of 10 M for 12 h to one of each duplicate. Cell lysates were
separated by electrophoresis for immunoblotting with the GFP-specific
antibody. The absence (–) or presence () of Cbz-L3 is indicated.
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enhanced CTL responses to the EBNA1 epitope. Although over-
all, CTL induction with the three different forms of ubiquiti-
nated EBNA1 was quite comparable, it is important to mention
here that animals immunized with Ub-Ala/Arg-EBNA1 and
Ub-Gly/Arg-EBNA1 (the two EBNA1 constructs with an unsta-
ble N-terminal residue) consistently induced slightly higher
CTL responses. These results are consistent with our earlier
conclusions that rapid intracellular degradation enhances CTL
epitope presentation from EBNA1 and thus overrides the GAr-
mediated inhibitory effect. The only limitation of these results
is that one may argue that this CTL priming may involve
exogenous loading by myocytes of intact EBNA1 antigen to
professional antigen presenting cells through cross priming.
Indeed, Blake et al. (22) have previously shown that the exog-
enous presentation of class I-restricted epitopes within EBNA1
is not inhibited by GAr sequences. However, it is unlikely that
the CTL responses in our study were induced by the uptake of
intact ubiquitinated protein released by myocytes because, as
stated above, ubiquitinated EBNA1 is rapidly degraded and is
barely detectable in cells expressing this protein. This argu-
ment is supported by previous studies that have shown only
high levels of antigen can efficiently cross-prime CD8 T cells,
whereas low dose antigens are ignored (24). We therefore favor
the hypothesis that the mechanism underlying the CTL prim-
ing of EBNA1 involves uptake of DNA, rather than intact
soluble protein by the antigen presenting cells in the draining
lymph nodes, and that when this DNA encodes a ubiquitinated
protein, an enhanced CTL response is observed. This argument
is also supported by earlier studies on CTL priming with DNA
immunization (25, 26).
FIG. 5. FACScan analysis of GFP fluorescence in DG75 cells transfected with expression vectors encoding EBNA1-GFP, Ub-Ala/
Met-EBNA1-GFP, Ub-Ala/Arg-EBNA1-GFP, or Ub-Gly/Arg-EBNA1-GFP. The number of GFP-positive cells were initially assessed at 24 h
PT. At the 24-h time point, these transfectants were split into two wells. Cells in one well were treated with Cbz-L3 (10 M), whereas transfectants
in the other well were left untreated. After 24 h (i.e. 48 h PT) GFP-positive cells were again assessed by FACScan. The percentage of GFP-positive
cells is indicated in each panel.
FIG. 6. Longitudinal analysis of
GFP-fluorescence in DG75 cells trans-
fected with expression vectors encod-
ing EBNA1-GFP, Ub-Ala/Met-EBNA1-
GFP, Ub-Ala/Arg-EBNA1-GFP, or Ub-
Gly/Arg-EBNA1-GFP. GFP-positive cells
were assessed at 24, 28, 32, 36, and 48 h PT
in the absence or presence of the protea-
some inhibitor Cbz-L3 (10 M). Results are
expressed as the percentage of GFP-posi-
tive cells relative to the number of fluoresc-
ing cells at 24 h PT for each transfectant.
Rapid Intracellular Degradation Overrides Proteasomal Block of EBNA133358
 at UQ Library on September 2, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
To further support our conclusions drawn from the murine
model, we also tested endogenous presentation of CTL epitopes
within EBNA1 using human EBV-specific CTL assays. This in
vitro testing was based on the endogenous presentation of a
well defined HLA B8-restricted CTL epitope (referred to as
FLR) that was inserted into the EBNA1 sequence near the C
terminus. Consistent with our data from the murine model,
human keratinocyte and B cell lines transfected with ubiquiti-
nated forms of EBNA1 showed higher levels of CTL-mediated
lysis compared with lysis of cells transfected with native
EBNA1 alone. This lysis was almost entirely blocked by incu-
bation with the proteasome inhibitor, Cbz-L3, suggesting that
specific targeting of EBNA1 through the ubiquitin-proteasome
pathway plays an important role in overriding the GAr-medi-
ated inhibitory effect.
Based on the results presented in this study, we speculate
that the GAr prevents not only proteasomal degradation but
also ubiquitination of native EBNA1 in virus-infected cells. It is
likely that the GAr-containing EBNA1 sequence folds in such a
way that a stable association with ubiquitin is not possible and
that this prevents polyubiquitination and hence results in in-
adequate targeting of this protein to the proteasomal complex.
The covalent linkage of ubiquitin, combined with N-end rule
targeting, overrides this blockage and allows efficient presen-
tation of CTL epitopes from EBNA1. These observations are
also supported by recent results based on the degradation
studies using GAr-fused GFP reporter substrates (27). Overall,
the data presented here have important implications for the
development of strategies designed to control EBV-associated
diseases. It is now well established that not only is EBNA1
expression critical for the long term persistence of EBV, but it
also acts as a fundamental factor in the pathogenesis of many
EBV-associated malignancies. Targeting this antigen through
immunological or biochemical intervention(s) could provide a
unique opportunity to manage the pathological consequences of
many EBV-associated diseases. Indeed, data presented here
provide, for the first time, encouraging evidence that it may be
possible to develop therapeutic strategies to modulate the sta-
bility of EBNA1 in normal and malignant cells. These strate-
gies may involve treatment of virus-infected cells with syn-
thetic or biological mediators capable of enhancing stable
ubiquitination and rapid intracellular degradation of EBNA1
in vivo. One such strategy recently proposed by Zhou et al. (28)
may involve manipulation of the ubiquitin-dependent proteo-
lytic machinery by targeting specific E3 ubiquitin-protein li-
gases to direct the degradation of otherwise stable cellular
proteins, such as EBNA1, in mammalian cells. Potentially, this
engineered proteolysis system could be used as a therapeutic
method to counteract the proteasomal block conferred on
EBNA1 through the cis-acting inhibitory GAr domain.
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